Telomere Shortening linked to Disability and Mitochondrial DNA Copy Number in Patients with Relapsing-Remitting Multiple Sclerosis

José Alfonso Cruz-Ramos*, Gabriela del Carmen López-Armas†, Eduardo Ignacio Diaz-Barba‡, Mónica Navarro-Meza§, Miguel Ángel Macias-Islas¶, Ana Miriam Saldaña-Cruz‡, Abraham Zepeda-Moreno*, Héctor Raúl Pérez-Gómez*, Alejandra Martínez-Hernández*, Martha Eloisa Ramos-Márquez*#

Abstract: Multiple sclerosis (MS) is a chronic autoimmune inflammatory disease that affects the nervous system. Peripheral blood leukocyte telomere length (LTL) and mitochondrial DNA copy number (mtDNA-CN) are potential biomarkers of disability and neurological damage. The present work evaluated LTL and mtDNA-CN in 75 relapsing-remitting MS (RRMS) patients 50 of whom had an Expanded Disability Status Scale (EDSS) 0 to 3 (mild-moderate disability), and 25 had an EDSS of 3.5 to 7 (severe disability). Absolute LTL and absolute mtDNA-CN were measured via real-time polymerase chain reaction (qPCR). The LTL and mtDNA-CN were significantly lower in RRMS severe disability than in RRMS mild-moderate disability (3.924 ± 0.124 vs 2.854 ± 0.092, p<0.00001; 75.14 ± 1.77 vs 68.06 ± 1.608, p<0.00001, respectively). The LTL and mtDNA-CN showed a linear correlation in RRMS with mild-moderate disability (r=0.2986, p=0.0351). In addition, in a binary logistic regression model the LTL can predict severe disability (AUC=0.697, p=0.0031, cutoff ≤ 3.0875 Kb, sensitivity= 73.1%, specificity=62.5%), the prediction is improved by including age to the model (AUC=0.765, p<0.0001, sensitivity=78.26%, specificity=81.25%). Aging is closely linked to the development of disability in RRMS and can be evaluated through LTL and mtDNA-CN absolute quantification.

Keywords: Leukocyte telomere length; Mitochondrial DNA; Relapsing-Remittent Multiple Sclerosis; Disability; Aging.
1. Introduction

Multiple sclerosis (MS) is a chronic autoimmune disease of multifactorial origin (genetic susceptibility and environmental factors) with a heterogeneous clinical behavior featuring neurological dysfunction secondary to central and peripheral nervous system damage (1–3). Globally, MS is the leading non-traumatic cause of neuronal disability in young adults, affecting approximately 2.8 million people (4). Demyelination and axonal loss in the central nervous system (CNS) is crucial for the episodic and irreversible progression of MS, they are mediated by an inflammatory phase followed by a neurodegenerative one (5). At the onset, patients with MS may have mild psychological and cognitive impairments, which progress to severe neurological and motor limitations (6,7). These neurodegenerative changes are assessed using the Expanded Disability Status Scale (EDSS) based on well-defined clinical and imaging parameters. Accordingly, patients are categorized from 0 (no signs, no symptoms) to 10 (death) (8–11). Patients with MS may have different phenotypes: primarily progressive multiple sclerosis (PPMS) manifests episodes of neurological dysfunction, is progressive and without recovery; relapsing-remitting multiple sclerosis (RRMS) characterized by episodes of neurological dysfunction with full or partial recovery, and finally, secondarily progressive multiple sclerosis (SPMS) results from an RRMS that acquires a PPMS-like pattern of progressive dysfunction without recovery (12). Neuroinflammation mechanisms in MS resemble those of aging but are seemingly activated early, exhibit greater intensity, and ultimately impact the course of the disease (13). Mitochondria and telomeres are closely linked to the aging process. Indeed, the core molecular mechanisms regulating aging are shared with the pathogenesis of most chronic degenerative diseases. Hence, the study of these common pathways is of current interest in MS research (14).

Telomeres are nucleoprotein structures that protect the ends of chromosomes, prevent deleterious structural changes such as intrachromosomal fusion, provide genomic stability, and regulate cellular senescence (15,16). Recently, a systematic review found that telomere length (TL) is consistently shorter in MS patients than in healthy controls. This association is independent of age and correlates with greater disability, lower brain volume, higher recurrence rate, and shorter conversion time from recurrent to progressive MS (17).

Another important factor associated with cellular aging and neurodegeneration in MS is the mitochondrial deficit (18). The mitochondrial DNA copy number (mtDNA-CN) reliably estimates the number of mitochondria in the cell (19). Studies focused on mtDNA-CN in MS, both in cerebrospinal fluid and lymphocytes, showed a significant decrease in mtDNA-CN in patients compared to controls (19,20). Furthermore, the Al-Kafaji study showed a significant decrease in mtDNA-CN in RRMS patients with more than ten years of diagnosis compared with those with less than ten years of diagnosis (19).

In the present study, we evaluated mtDNA-CN and leukocyte telomere length (LTL) as biomarkers to predict disability in patients with RRMS. Research insights into the link between aging and neurodegeneration can help classify MS patients according to prognosis and to design therapeutic strategies to prevent accelerated aging in MS.

2. Results

2.1. Patients

Seventy-five patients with RRMS, one group of 50 RRMS with mild to moderate disability (EDSS from 0 to 3), and the other group of 25 RRMS patients with severe disability (EDSS from 3.5 to 7), were enrolled. Of the total number of patients, there were 50 women and 25 men. The mean age was 39.48±11.52, mean years since diagnosis was 8.607 (±5.881), mean progression rate was 0.6726±0.8374, and the mean EDSS
There was no significant difference regarding sex, age, or time since diagnosis between the 2 study groups. There was significant difference regarding progression rate and EDSS. The EDSS of the RRMS with mild disability group (EDSS 0 to 3) was 1.91±0.8846 and the EDSS of the RRMS with advanced disability group (EDSS 3.5 to 7) was 4.9±1.109 (Table 1).

Table 1. Characteristics of groups of patients and their pharmacological treatments. Group 1 with mild to moderate disability (EDSS 0-3) and group 2 with severe disability (EDSS 3.5-7).

| Characteristic             | Group 1, n=50 | Group 2, n=25 |
|----------------------------|---------------|---------------|
|                           | “Mild-moderate disability” | “Severe disability” |
| Female                     | 33 (66%)      | 17 (68%)      |
| Male                       | 17 (34%)      | 8 (32%)       |
| Age                        | 37.70 (± 11.409) | 43.04 (± 11.110) |
| Years since diagnosis      | 7.78 (± 5.1211) | 10.26 (± 6.9868) |
| EDSS*                      | 1.91 (± 0.8846) | 4.9 (± 1.109)  |
| Progression rate*          | 0.5139 (± 0.6355) | 0.9898 (± 1.0864) |

Treatment:
- Glatiramer Acetate: 19 (38%) | 9 (36%)
- Rituximab: 4 (8%) | 3 (12%)
- Interferon β: 14 (28%) | 5 (2%)
- Fingolimod: 5 (10%) | 2 (8%)
- Azathioprine: 0 | 3 (12%)
- Natalizumab: 1 (2%) | 1 (4%)
- Dimethyl fumarate: 3 (6%) | 1 (4%)
- None: 4 (8%) | 1 (4%)

EDSS=Expanded Disability Status Scale
Progression rate= EDSS/years with the disease
*p<0.05. Progression rate comparison by student T test and EDSS by Mann Whitney test.

2.2 Absolute LTL and mtDNA-CN in mild-moderate disability vs. severe disability

Comparisons of LTL (3.924 ± 0.124 vs. 2.854 ± 0.090) and mtDNA-CN (75.14 ± 1.77 vs. 68.06 ± 1.60) between the groups with mild-moderate disability and severe disability were significant (Figure 1).
2.3 Correlation between LTL and mtDNA-CN

Pearson’s correlation test was significant in the mild-moderate disability group (Figure 2). There was no correlation in the severe disability group.

2.4 Telomere Disability Prediction

The predictive capacity of LTL was evaluated directly (raw data), the receiver-operating characteristic (ROC) curves was significant ($p = 0.003$), and the area under the curve (AUC) was 0.697. The cut-off point was obtained through the Youden index,
and the associated criterion was ≤ 3.0875 Kb, which showed a sensitivity of 73.1% and specificity of 62.5%, positive predictive value (PPV) of 48.6%, and negative predictive value (NPV) of 83.3% (Figure 3).

![Figure 3](image)

**Figure 3.** Receiver-operating characteristic (ROC) curves for LTL (raw data) in patients with RRMS. AUC: Area under the curve.

### 2.5 Binary Logistic Regression Model of LTL and Age

Predictive models based on binary logistic regression were developed. Of the variables introduced, only the LTL was significant in Wald test (Table 2). However, the integration of age together with LTL improved the precision of the model, which did not occur with the rest of the variables.

| Variable              | Odds ratio | 95% CI          | p     |
|-----------------------|------------|-----------------|-------|
| LTL*                  | 0.5855     | 0.3672 to 0.9336 | 0.0245|
| mtDNA-CN              | 0.9980     | 0.9810 to 1.0152 | 0.8142|
| Age                   | 1.0331     | 0.9789 to 1.0903 | 0.2362|
| Sex (female)          | 1.0040     | 0.3057 to 3.2974 | 0.8143|
| Years since diagnosis | 1.0585     | 0.9572 to 1.1706 | 0.2678|

LTL: Leukocyte telomere length; mtDNA-CN: mitochondrial DNA copy number.

* p<0.05, Wald test. CI = confidence interval
LTL and age had the highest precision and was the most appropriate according to Akaike’s criteria (AUC = 0.765, p < 0.0001, sensitivity = 78.26%, specificity = 81.25%, PPV = 66.7 and NPV = 88.6%) (Figure 4). Pairwise comparison of ROC curves, between LTL and age versus LTL did not reach significance (p=0.1429), so the equivalence of the models (LTL and age vs. LTL alone) was not ruled out (Figure 5). LTL maintains significance even when controlling for variables.

Figure 4. Receiver-operating characteristic (ROC) curve for binary logistic regression model for LTL and age in patients with RRMS. AUC: Area under the curve.

Figure 5. Pairwise comparison of ROC curves, between LTL and age versus LTL alone did not reach significance (Z statistic = 1.465, p= 0.1429).
3. Discussion

In recent years, MS has been approached from the perspective of biological aging as the trigger of the cellular and immunological changes involved in the development of neuroinflammation, neurodegeneration, and disability. Several authors consider that, among the multiple factors underlying neurodegeneration, accelerated neurological aging occurs in MS. Telomeres are found at the ends of chromosomes and are made up of repeats of the hexanucleotide TTAGGG, a non-coding sequence spanning from 5 to 15 kilobases (15,16). Telomere changes contribute to the pathogenesis of several multifactorial chronic diseases, including neurological disorders. Loss of chromosomal integrity due to shorten telomeres facilitates fusions with other chromosomes, mutations, and other events that impair cell function, decrease cell division, and lead to cell aging (21,22).

Mitochondria is an organelle that regulate intracellular calcium homeostasis, ATP generation, programmed cell death (apoptosis), reactive oxygen species (ROS) production, and aging processes, all of which affect the telomere structure and function (23). Numerical and structural alterations of mitochondria is pathogenic, especially in high-energy-demanding tissues such as muscle and the nervous system(24). Age and accelerated aging are factors of neurological deterioration in MS. Age is considered a strong independent factor to develop a progressive MS phenotype via complex and multidirectional interactions with aging and degenerative processes (25,26). In this sense, the telomeres and mitochondria are two of the most important cellular components in the regulation of aging and disease (Figure 6).

![Diagram showing telomere shortening and decrease in mitochondrial DNA copy number is associated with severe disability.](image)

**Figure 6.** LTL and mtDNA-CN decrease in severe disability. EDSS = Expanded Disability Status Scale.

The patients enrolled in this study were primarily young (mean 39.48 ± 11.52 years) and selected in such a way that the distribution of MS was similar in both sexes and to the proportion of mild-moderate/severe disability observed in the general population; hence,
the effect of sex and age on LTL or mtDNA-CN was minimized. The wide variability of LTL and mtDNA-CN reflects the interactions of organisms with environmental factors and the influence of endogenous factors (genes, hormones, ROS, among others); notably, up to 70% of the variance of TL is explained by heritability (27,28).

Although the variability in TL is determined by multiple factors, in the group with a mild-moderate disability, we found a low but significant linear correlation ($r^2=0.0891$, $p=0.0351$) between LTL and mtDNA-CN. Even if a similar finding was previously documented in elderly women (29), our study is the first to correlate these two senescence parameters in patients with MS. The lack of such a correlation in the severe disability group suggests that this correlation was lost in advanced disability stages due to greater heterogeneity in the processes of aging and neurodegeneration, as well as by the influence of other factors such as increased immune activation, chronic inflammation, and age (13,30). The bidirectional interaction between mitochondria and TL result from different mechanisms related to mitochondrial function, such as oxidative stress, apoptosis, energy efficiency of the respiratory chain, and chronic inflammation. Of note, all of these can produce telomere shortening and subsequent exposure of subtelomeric DNA, which in turn affect mitochondrial function through activation of genes that prevent genetic damage such as p53 and p21(31). The aging is fundamental for the progression of disability; actually, senescent changes have been identified in multiple cell lineages of the nervous system that are affected during the evolution of MS, such as neurons, microglia, oligodendrocytes, and astrocytes (32–36). In addition, we compared the absolute quantification of LTL and mtDNA-CN in mild-moderate disability patients versus patients with severe disability and found significant differences for both parameters ($3.924 \pm 0.124 \text{ vs } 2.854 \pm 0.092$, $p<0.00001$; $75.14 \pm 1.77 \text{ vs } 68.06 \pm 1.608$, $p<0.00001$, respectively); thus, such discrepancies support the interdependence of LTL and mtDNA-CN in the different phases of disability in MS.

Telomere biology and age play a crucial role in health and disease. In several studies, age has been reported as one of the most important factors for conversion of a RRMS into SPMS (37–39). This clinical distinction reflects the underlying neurological damage: in the former phenotype the damage is predominantly inflammatory whereas in the progressive phenotype it is neurodegenerative (5,40). Moreover, LTL can serve as a biomarker of immunesenescence and has been linked to the progression of neurological damage (38); thereby, LTL could be useful for assessing and predicting disability in MS(41). We have found LTL to be an independent predictor of disability. After integrating possible predictors (LTL, mtDNA-CN, sex, age, and time with the disease) to the binary logistic regression model, only age and LTL were useful for prediction. The ROC curve for direct LTL values alone has moderate predictive capability ($AUC = 0.697$, $p = 0.003$, cutoff $\leq 3.0875 \text{ Kb}$, sensitivity = 73.1 %, specificity = 62.5 %, PPV = 48.6 %, NPV = 83.3 %). The high NPV of LTL identifies LTL as a relevant biomarker for assessing disability status. Interestingly, when LTL and age were combined in the binary logistic regression model, accuracy increased ($AUC: 0.765$, $p < 0.001$, sensitivity = 78.26 %, specificity = 81.25 %, PPV = 66.7 %, NPV = 88.6 %). Although LTL and age are related risk factors that predict disability, LTL remains as a disability factor even when analyzed independently from other variables. This is of great importance since age is the highest prognostic factor for MS progression (42); however, LTL can be as strong or even stronger than age as a predictor of disability status and/or disease progression in MS.

More studies, especially longitudinal ones with large samples that fully address the different MS phenotypes, are required to establish the clinical utility of LTL for the evaluation and prediction of disability, as well as to unravel the molecular mechanisms involved in the process of neuroinflammation, neurodegeneration, and aging and its
relationship with the structure and function of telomeres and mitochondria in MS.

4. Materials and Methods

4.1 Design of the study

The present research is a cross-sectional observational study. We enrolled 75 patients randomly (50 women and 25 men) aged between 18 and 66 years old with RRMS without comorbidities (cancer, diabetes, hypertension, or other immunologic diseases), previously diagnosed, evaluated, and classified with EDSS by a neurologist. All patients fulfilled the McDonald diagnostic criteria (38). Group 1 (EDSS 0-3) with mild-moderate disability (n=50) and group 2 (EDSS 3.5-7) with severe disability (n=25). All patients were recruited from the Institute of Experimental Clinical Therapy (INTEC) MS cohort, University Center of Health Sciences (CUCS) of the University of Guadalajara (Figure 7). In addition, age, time after disease onset, disease progression index and actual treatment were recorded in both groups. This study complies with the Declaration of Helsinki guidelines. The ethics committee of the CUCS approved the study with the number CI-03519. All participants involved in the study signed informed consent.

4.2 Absolute quantification of telomere length and mtDNA copy number

Total venous blood samples were collected for separation of leukocyte and DNA extraction by Miller method, once obtained were stored at −20 °C until analysis (39). The quantification of mtDNA-CN and LTL was assessed by the commercial assay kit Absolute Human Telomere Length and Mitochondrial DNA Copy Number Dual Quantification qPCR (ScienCell Research Laboratories, San Diego, CA, USA) according to the manufacturer’s protocol. For PCR reaction (per sample): 10 μL of 2X GoldNStart TaqGreen qPCR
master mix, 2 μL of primer solution (Tel, mtDNA or SCR), 7 μL of nuclease-free water, and 1 μL of DNA problem (5 ng). Initial denaturation at 95°C for 10 min, followed by 32 cycles with denaturation (95°C for 20 sec), hybridization (52°C for 20 sec), and extension (72°C for 45 sec). As a constituent region, a region of 100 bp length is used on chromosome 17, which is recognized by the first set of SCR (single copy reference). A reference DNA with a known concentration (telomere length 348 ± 11 kb per diploid cell; 1.27± 0.03 x 103 copies of mtDNA per diploid cell) was also available.

4.3 Statistical analysis

The statistical analysis consisted of descriptive statistics (means, frequencies and percentages) to describe the groups of patients. The Anderson-Darling (n > 30) or D’Agostino-Pearson (n < 30) tests were used to evaluate the normality of the data. The outliers were identified with the Rout method. For the comparison between the groups of patients with mild-moderate disability vs. severe disability, inferential statistics were used with parametric tests such as Student’s T for variables with normal distribution; Mann’s U test was used for variables with non-normal distribution; Chi square test or Fisher’s exact test was used for the comparison of frequencies. The predictive capacity (sensitivity, specificity, PPV and NPV) was evaluated with ROC curves. To predict severe disability, binary logistic regression models were developed, which were evaluated with the Akaike corrected information criterion and the Z statistic for comparison of ROC curves (LTL vs. Age vs. LTL + Age). All analysis were performed using GraphPad Prism version 9.02 for Windows (La Jolla California USA, www.graphpad.com) and MedCalc Statistical Software version 15.8 (Ostend, Belgium; https://www.medcalc.org).

Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Figure S1: title, Table S1: title, Video S1: title.

Author Contributions: Conceptualization of this research was made by J.A.C.R; G.C.L.A and M.E.R.M; methodology was developed by E.I.D.B; validation of qPCR was supported by A.Z.M and M.N.M; formal analysis, J.A.C.R.; investigation, M.A.M.I and A.M.S.C; sample recollection, A.M.H; resources, H.R.P.G.; data curation, J.A.C.R and E.I.D.B.; writing—original draft preparation, J.A.C.R; G.C.L.A and M.E.R.M; writing—review and editing, J.A.C.R; G.C.L.A, and M.E.R.M visualization, A.M.S.C.; supervision, M.A.M.; project administration, H.R.P.G.; funding acquisition, J.A.C.R. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by PROSNI 2021 of the University of Guadalajara.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the ethics committee of the CUCS with the number CI-03519.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: https://figshare.com/articles/dataset/TLT_mtDNA_MS/17097470

Acknowledgments: We are deeply grateful to Dr. Horacio Rivera Ramirez for proper revision of this manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Goodin DS. The causal cascade to multiple sclerosis: A model for MS pathogenesis. PLoS One. 2009;4(2).
2. Goodin DS. Chapter 11 - The epidemiology of multiple sclerosis: insights to disease pathogenesis. In: Goodin DS;T-H of CN, editor. Multiple Sclerosis and Related Disorders [Internet]. Elsevier; 2014. p. 231–66. Available from: https://www.sciencedirect.com/science/article/pii/B9780444520012000108
3. Goodin DS. The epidemiology of multiple sclerosis: insights to a causal cascade. Handb Clin Neurol [Internet]. 2016;138:173–206. Available from: https://pubmed.ncbi.nlm.nih.gov/27637959/
4. Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler [Internet]. 2020;26(14):1816–21. Available from: https://pubmed.ncbi.nlm.nih.gov/33174475/  
5. Reich DS, Luchinetti CF, Calabresi PA. Multiple Sclerosis. N Engl J Med [Internet]. 2018 Jan 10;378(2):169–80. Available from: https://doi.org/10.1056/NEJMra1401483  
6. Macías Islas MÁ, Ciampi E. Assessment and Impact of Cognitive Impairment in Multiple Sclerosis: An Overview. Biomedicines. 2019 Mar;7(1).  
7. Lilia N. Esclerosis múltiple. 2007;8(1):57–66.  
8. Cadavid D, Tang Y, O’Neill G. [Responsiveness of the Expanded Disability Status Scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis], Rev Neurol. 2010 Sep;51(6):321–9.  
9. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology [Internet]. 1983;33(11):1444–52. Available from: https://pubmed.ncbi.nlm.nih.gov/6685237/  
10. Kurtzke JF. On the origin of EDSS. Mult Scler Relat Disord [Internet]. 2015 Mar;4(2):95–103. Available from: https://pubmed.ncbi.nlm.nih.gov/25787185/  
11. Şen S. Neurostatus and EDSS Calculation with Cases. Noro Psikiyatr Ars [Internet]. 2018;55(Suppl 1):S80–3. Available from: https://pubmed.ncbi.nlm.nih.gov/30692865/  
12. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology [Internet]. 2014 Jul;83(3):278. Available from: /pmc/articles/PMC4117366/  
13. Musella A, Gentile A, Rizzo FR, Vito F De, Fresenega D, Bullitta S, et al. Interplay between age and neuroinflammation in multiple sclerosis: Effects on motor and cognitive functions. Front Aging Neurosci. 2018;10(AUG):1–13.  
14. Paterniani S, Fossati V, Bonora M, Giorgi C, Marchi S, Missiroli S, et al. Mitochondria in Multiple Sclerosis: Molecular Mechanisms of Pathogenesis. Int Rev Cell Mol Biol. 2017;328:49–103.  
15. Saretski G. Telomeres, Telomerase and Ageing. Subcell Biochem [Internet]. 2018;90:221–308. Available from: https://pubmed.ncbi.nlm.nih.gov/30799012/  
16. Moyzis RK, Buckingham JM, Cram LS, Dani M, Deaven LL, Jones MD, et al. A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci U S A [Internet]. 1988;85(18):6622–6. Available from: https://pubmed.ncbi.nlm.nih.gov/3413114/  
17. Bühring J, Hecker M, Fitzner B, Zettl UK. Systematic review of studies on telomere length in patients with multiple sclerosis. Aging Dis. 2021;12(5):1272–86.  
18. Mao P, Reddy PH. Is multiple sclerosis a mitochondrial disease? Biochim Biophys Acta Mol Basis Dis [Internet]. 2010;1802(1):66. Available from: /pmc/articles/PMC2970545/  
19. Al-Kafaji G, Bakheit HF, Alharbi MA, Farahat AA, Jailani M, Ebrahin BH, et al. Mitochondrial DNA Copy Number in Peripheral Blood as a Potential Non-invasive Biomarker for Multiple Sclerosis. Neuromolecular Med. 2020 Jun;22(2):304–13.  
20. Lowes H, Pyle A, Duddy M, Hudson G. Cell-free mitochondrial DNA in progressive multiple sclerosis. Mitochondrion [Internet]. 2018/08/08. 2019 May;46:307–12. Available from: https://pubmed.ncbi.nlm.nih.gov/30098422  
21. Anitha A, Thanseem I, Vasu MM, Viswambharan V, Poovathinal SA. Telomeres in neurological disorders. Adv Clin Chem [Internet]. 2019;90:61–132. Available from: https://pubmed.ncbi.nlm.nih.gov/31122612/  
22. Wang S, Madu CO, Lu Y. Telomere and Its Role in Diseases. Oncomedicine. 2019 Feb;4(1):1–9.  
23. Zheng Q, Huang J, Wang G. Mitochondria, Telomeres and Telomerase Subunits. Front Cell Dev Biol. 2019;7(11):1–10.  
24. Lezi E, Swerdlow RH. Mitochondria in Neurodegeneration. Adv Exp Med Biol [Internet]. 2012;942:269. Available from: /pmc/articles/PMC3618469/  
25. Scalari A, Neuhaus A, Daumer M, Ebers GC, Muraro PA. Age and disability accumulation in multiple sclerosis. Neurology [Internet]. 2011 Sep;77(13):1246–52. Available from: /pmc/articles/PMC2790545/  
26. Al-Kafaji G, Bakheit HF, Alharbi MA, Farahat AA, Jailani M, Ebrahin BH, et al. Mitochondrial DNA Copy Number in Peripheral Blood as a Potential Non-invasive Biomarker for Multiple Sclerosis. Neuromolecular Med. 2020 Jun;22(2):304–13.  
27. Hjelmborg JB, Dalgård C, Möller S, Steenstrup T, Kimura M, Christensen K, et al. The heritability of leucocyte telomere length: A meta-analysis. PLoS One [Internet]. 2016 May;11(5):e0155123. Available from: https://doi.org/10.1371/journal.pone.0155123  
28. Broer L, Codd V, Nyholt DR, Deelen J, Mangino M, Willemsen G, et al. Meta-analysis of telomere length in 19 713 subjects from the Atlas of MS, third edition. Mult Scler [Internet]. 2020;26(14):1816–21. Available from: https://pubmed.ncbi.nlm.nih.gov/25787185/  
29. Al-Kafaji G, Bakheit HF, Alharbi MA, Farahat AA, Jailani M, Ebrahin BH, et al. Mitochondrial DNA Copy Number in Peripheral Blood as a Potential Non-invasive Biomarker for Multiple Sclerosis. Neuromolecular Med. 2020 Jun;22(2):304–13.  
30. Kordinas V, Ioannidis A, Chatzipanagiotou S. The Telomere/Telomerase System in Chronic Inflammatory Diseases. Cause or Effect? Genes (Basel) [Internet]. 2015;52(5):297–302. Available from: https://pubmed.ncbi.nlm.nih.gov/25770094/  
31. Passos JF, Saretzki G, Ahmed S, Nelson G, Richter T, Peters H, et al. Mitochondrial dysfunction accounts for the stochastic heterogeneity in telomere-dependent senescence. PLoS Biol [Internet]. 2007 May;5(5):1138–51. Available from: https://pubmed.ncbi.nlm.nih.gov/17472436/  
32. Pertusa M, García-Matas S, Rodríguez-Farré E, Sanfeliz C, Cristófol R. Astrocytes aged in vitro show a decreased neuroprotective capacity. J Neurochem [Internet]. 2007 May;101(3):794–805. Available from: https://pubmed.ncbi.nlm.nih.gov/17250685/
33. Mansour H, Chamberlain CG, Weible MW, Hughes S, Chu Y, Chan-Ling T. Aging-related changes in astrocytes in the rat retina: imbalance between cell proliferation and cell death reduces astrocyte availability. Aging Cell [Internet]. 2008;7(4):526–40. Available from: https://pubmed.ncbi.nlm.nih.gov/18489730/
34. Al-Mashhadi S, Simpson JE, Heath PR, Dickman M, Forster G, Matthews FE, et al. Oxidative Glial Cell Damage Associated with White Matter Lesions in the Aging Human Brain. Brain Pathol [Internet]. 2015 Sep;25(5):565–74. Available from: https://pubmed.ncbi.nlm.nih.gov/25311358/
35. Jurk D, Wang C, Miwa S, Maddick M, Korolchuk V, Tsolou A, et al. Postmitotic neurons develop a p21-dependent senescence-like phenotype driven by a DNA damage response. Aging Cell [Internet]. 2012;11(6):996–1004. Available from: https://pubmed.ncbi.nlm.nih.gov/22882466/
36. Martínez-Cué C, Rueda N. Cellular Senescence in Neurodegenerative Diseases. Front Cell Neurosci. 2020 Feb;14:16.
37. Gray V, Arnett P. Aging with multiple sclerosis: cognitive, emotional and neuropathological considerations. Neurodegener Dis Manag. 2014;4(2):187–94.
38. Miner AE, Graves JS. What telomeres teach us about MS. Mult Scler Relat Disord [Internet]. 2021;54:103084. Available from: https://doi.org/10.1016/j.msard.2021.103084
39. Leray E, Yaouanq J, Le Page E, Costans M, Laplaud D, Oger J, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain [Internet]. 2010/04/27. 2010 Jul;133(Pt 7):1900–13. Available from: https://pubmed.ncbi.nlm.nih.gov/20423930
40. Cree BAC, Reich DE, Khan O, De Jager PL, Nakashima I, Takahashi T, et al. Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA. Arch Neurol. 2009 Feb;66(2):226–33.
41. Krysko KM, Henry RG, Cree BAC, Lin J, University of California SFM-ET, Caillier S, et al. Telomere Length Is Associated with Disability Progression in Multiple Sclerosis. Ann Neurol [Internet]. 2019 Nov 1;86(5):671–82. Available from: https://doi.org/10.1002/ana.25592
42. Ghione E, Bergsland N, Dwyer MG, Hagemeier J, Jakimovski D, Paunksi I, et al. Aging and Brain Atrophy in Multiple Sclerosis. J Neuroimaging. 2019;29(4):527–35.